Gallivac IB88 Neo Bruistablet voor vernevelsuspensie

Authorised

- Avian infectious bronchitis virus, type 793/B, strain CR88121, Inactivated

Product identification

Medicine name:
Gallivac IB88 Neo Bruistablet voor vernevelsuspensie
Gallivac IB88 Neo Comprimé effervescent pour suspension pour inhalation par nébuliseur
Gallivac IB88 Neo Brausetablette zur Herstellung einer Suspension für einen Vernebler

Active substance:
Avian infectious bronchitis virus, type 793/B, strain CR88121, Inactivated

Target species:
Poultry

Route of administration:
Nebulisation use

Product details

Active substance and strength:
Avian infectious bronchitis virus, type 793/B, strain CR88121, Inactivated

4.00 log 10 50% embryo infective dose / 1.00 Other

Pharmaceutical form:
Effervescent tablet

Withdrawal period by route of administration:
Nebulisation use:

- **Poultry**
  - Meat and offal. no withdrawal period 0 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD07

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Belgium

Available in:
Belgium

Package description:
Gallivac IB88 Neo 100 2000 doses Effervescent tablets for nebuliser suspension in blister of 10 tablets
Gallivac IB88 Neo 10 2000 doses Effervescent tablets for nebuliser suspension in blister of 10 tablets
Gallivac IB88 Neo 100 1000 doses Effervescent tablets for nebuliser suspension in blister of 10 tablets
Gallivac IB88 Neo 10 1000 doses Effervescent tablets for nebuliser suspension in blister of 10 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Animal Health Belgium S.A.

Marketing authorisation date:
28/11/2016

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V502986

Date of authorisation status change:
2/02/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.